Growth Differentiation Factor-15 Is a Useful Prognostic Marker in Patients With Heart Failure With Preserved Ejection Fraction
Yasuhiro Izumiya(Kumamoto University), Hisao Ogawa(Kumamoto University Hospital), Kenichi Tsujita(Kumamoto University), Yuichi Kimura(Kumamoto University), Shinsuke Hanatani(Kumamoto University), Taku Rokutanda(Kumamoto University), Tomoko Tanaka(Kumamoto University), Eiichiro Yamamoto(Kumamoto University), Seiji Hokimoto(Kumamoto University), Sunao Kojima(Kumamoto University), Koichi Kaikita(Kumamoto University), Megumi Yamamuro(IRYO Sosei University), Satoshi Araki(Kumamoto University), Hiroaki Kusaka(Kumamoto University), Seiji Takashio(Kumamoto University), Shinji Tayama(Saiseikai Kumamoto Hospital), Takanori Tokitsu(Kumamoto University)
Cited by 77
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
|The Lancet|2017|1.3k
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
|New England Journal of Medicine|2011|753
Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention
|Journal of the American College of Cardiology|2015|449